Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study

INTRODUCTION: Sunitinib is a standard of care first line treatment for patients with metastatic renal cell carcinoma (RCC). Sunitinib standard dose is 50 mg once daily for 4 consecutive weeks followed by 2 weeks’ off (4/2 schedule). Long-term and high exposure to this medication lead to severe adver...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Contemp Oncol (Pozn)
Autors principals: Abdelaziz, Lobna A., Taha, Heba F., Ali, Magid M., Abdelgawad, Marwa I., Elwan, Amira
Format: Artigo
Idioma:Inglês
Publicat: Termedia Publishing House 2021
Matèries:
Original Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7836283/
https://ncbi.nlm.nih.gov/pubmed/33531869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2020.102802
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars